- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
| 13.02. | P3 Health Partners strebt Profitabilität bis 2025 mit Umsatz von bis zu 1,5 Milliarden US-Dollar an | 11 | Investing.com Deutsch | ||
| 13.02. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.24 | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11.24 | P3 Health Partners GAAP EPS of -$0.31 misses by $0.27, revenue of $362.1M beats by $2.21M | 4 | Seeking Alpha | ||
| 12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 151 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
| 12.11.24 | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.09.24 | Hedge Fund and Insider Trading News: Ray Dalio, Chris Rokos, Robert Citrone, Engine Capital, Citadel Investment Group, Bridgewater Associates, Eisler Capital, Viasat Inc (VSAT), P3 Health Partners Inc (PIII), and More | 1 | Insider Monkey | ||
| 14.09.24 | Chicago Pacific Founders buys P3 Health shares worth over $81k | 1 | Investing.com | ||
| 13.09.24 | Chicago Pacific Founders entities buy P3 Health Partners shares worth $128k | 1 | Investing.com | ||
| 11.09.24 | P3 Health Partners sees insider buying, shares acquired at $0.47-$0.52 range | 2 | Investing.com | ||
| 07.08.24 | P3 Health Partners Announces Second Quarter 2024 Results | 115 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
| 08.05.24 | P3 Health Partners Announces First Quarter 2024 Results | 163 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,130 | -2,26 % | Sernova Biotherapeutics Inc: Sernova receives FDA clearance for IND application | ||
| ATOSSA THERAPEUTICS | 0,726 | +2,98 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,963 | +1,56 % | Ping An Healthcare and Technology Company Limited: Ping An Health Pioneers AI-Driven Healthcare with DeepSeek Integration | HONG KONG and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,022 | +18,48 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,510 | +10,87 % | Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance | The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/... ► Artikel lesen | |
| CYTOSORBENTS | 1,060 | +7,29 % | CytoSorbents sichert sich 1,6 Millionen US-Dollar durch Optionsscheinausübungen | ||
| VERU | 0,472 | -1,99 % | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,770 | +2,67 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
| VOLITIONRX | 0,591 | -4,88 % | VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for
Friday, November 15 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., Nov. 14, 2024... ► Artikel lesen | |
| EKSO BIONICS | 0,498 | +7,56 % | EKSO BIONICS HOLDINGS, INC. Q4 Sales Increase | ||
| IMUNON | 0,765 | -7,27 % | Imunon, Inc.: IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study | IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in... ► Artikel lesen | |
| BEYOND AIR | 0,256 | +3,23 % | Beyond Air Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update | Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger, Inc.: Avinger Reports Third Quarter 2024 Results | Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company... ► Artikel lesen | |
| NOVACYT | 0,571 | 0,00 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
| AROVELLA THERAPEUTICS | 0,062 | +4,20 % | XFRA E4NA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
P3 HEALTH PARTNERS INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,184 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu P3 HEALTH PARTNERS INC finden Sie auf Wallstreet Online.
